Tilray Brands (NASDAQ:TLRY) Trading Up 4% – Time to Buy?

Tilray Brands, Inc. (NASDAQ:TLRY)’s stock price was up 4% during trading on Friday . The company traded as high as $4.66 and last traded at $4.64. 3,148,211 shares changed hands during mid-day trading, a decline of 26% from the average session volume of 4,280,151 shares. The stock had previously closed at $4.46.

More Tilray Brands News

Here are the key news stories impacting Tilray Brands this week:

• Positive Sentiment: Tilray Medical said it is expanding access to medical cannabis for veterans through its Lyphe Clinic at Aldershot’s Armed Forces Weekend in the UK, supporting its regulated medical cannabis strategy and reinforcing the benefits of its Lyphe Group acquisition. Article Title
• Positive Sentiment: Breckenridge Distillery, a Tilray subsidiary, won top honors at the San Francisco World Spirits Competition, with Rum Cask Finish earning the highest award and Honey Whiskey taking gold, which may support Tilray’s premium beverage portfolio and brand strength. Article Title
• Positive Sentiment: Tilray-linked craft beer brands BrewDog and Montauk Brewing are continuing community and product launches, including BrewDog Inverurie’s reopening and Montauk’s anniversary celebration and limited beer release, which may help maintain consumer engagement across Tilray’s beverage segment. Article Title
• Neutral Sentiment: A recent market recap noted Tilray’s shares fell more than the broader market in the prior session, reflecting ongoing investor caution around the stock. Article Title
• Negative Sentiment: Investor sentiment may also be weighed by the broader report that Tilray has seen fresh short-interest activity, which can signal continued skepticism about the stock’s near-term outlook.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the company. TD Cowen cut their price target on Tilray Brands from $10.00 to $7.00 and set a “buy” rating for the company in a report on Monday, March 30th. Wall Street Zen upgraded Tilray Brands from a “sell” rating to a “hold” rating in a research report on Saturday, March 21st. Weiss Ratings lowered shares of Tilray Brands from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, May 13th. Roth Mkm raised shares of Tilray Brands from a “neutral” rating to a “buy” rating and set a $10.00 target price for the company in a report on Thursday, April 2nd. Finally, ATB Cormark Capital Markets reduced their price target on shares of Tilray Brands from $9.50 to $9.00 and set a “sector perform” rating on the stock in a research report on Thursday, April 2nd. Three investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Tilray Brands has an average rating of “Hold” and an average price target of $11.50.

Tilray Brands Trading Up 4.0%

The stock has a market cap of $540.79 million, a P/E ratio of -0.34 and a beta of 1.88. The company has a debt-to-equity ratio of 0.19, a quick ratio of 1.66 and a current ratio of 2.79. The stock’s fifty day moving average is $5.59 and its 200 day moving average is $7.26.

Tilray Brands (NASDAQ:TLRY) last issued its quarterly earnings data on Wednesday, April 1st. The company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.10). Tilray Brands had a negative return on equity of 3.31% and a negative net margin of 156.51%.The company had revenue of $206.73 million for the quarter, compared to the consensus estimate of $201.35 million. During the same period in the previous year, the firm earned ($0.87) earnings per share. As a group, equities research analysts predict that Tilray Brands, Inc. will post -0.58 earnings per share for the current fiscal year.

Insider Buying and Selling at Tilray Brands

In other news, Director David G. Hopkinson sold 33,556 shares of the business’s stock in a transaction that occurred on Tuesday, April 21st. The stock was sold at an average price of $6.94, for a total transaction of $232,878.64. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 0.84% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Tidal Investments LLC increased its position in Tilray Brands by 15.0% during the second quarter. Tidal Investments LLC now owns 28,971,835 shares of the company’s stock valued at $12,006,000 after acquiring an additional 3,776,410 shares during the last quarter. Millennium Management LLC raised its stake in shares of Tilray Brands by 281.0% in the third quarter. Millennium Management LLC now owns 4,942,319 shares of the company’s stock valued at $8,550,000 after acquiring an additional 3,645,060 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in shares of Tilray Brands in the 3rd quarter worth about $5,813,000. Ausdal Financial Partners Inc. bought a new stake in shares of Tilray Brands in the 2nd quarter worth about $939,000. Finally, Swiss National Bank boosted its stake in shares of Tilray Brands by 4.4% during the 3rd quarter. Swiss National Bank now owns 2,013,038 shares of the company’s stock worth $3,483,000 after purchasing an additional 84,900 shares during the period. 9.35% of the stock is owned by hedge funds and other institutional investors.

Tilray Brands Company Profile

Tilray Brands, Inc is a global cannabis-lifestyle and consumer packaged goods company engaged in the cultivation, production, distribution and sale of cannabis and cannabinoid-based products. The company develops and markets a diverse portfolio of branded products spanning medical cannabis, adult-use recreational products and wellness offerings. Through state-of-the-art cultivation facilities, research and development efforts, and quality control systems, Tilray Brands aims to deliver consistent, scalable products for a range of patient and consumer needs.

Tilray’s product lineup includes cannabis flower, pre-rolls, oils and tinctures, vapes, edibles and topicals, as well as hemp-derived cannabidiol (CBD) products.